Display Settings:

Format

Send to:

Choose Destination

    Infect Immun. 2006 Aug;74(8):4939-44.

    Intranasal immunization with the cholera toxin B subunit-pneumococcal surface antigen A fusion protein induces protection against colonization with Streptococcus pneumoniae and has negligible impact on the nasopharyngeal and oral microbiota of mice.

    Pimenta FC, Miyaji EN, Arêas AP, Oliveira ML, de Andrade AL, Ho PL, Hollingshead SK, Leite LC.

    Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, Brazil.

    One of the candidate proteins for a mucosal vaccine antigen against Streptococcus pneumoniae is PsaA (pneumococcal surface antigen A). Vaccines targeting mucosal immunity may raise concerns as to possible alterations in the normal microbiota, especially in the case of PsaA, which was shown to have homologs with elevated sequence identity in other viridans group streptococci. In this work, we demonstrate that intranasal immunization with a cholera toxin B subunit-PsaA fusion protein is able to protect mice against colonization with S. pneumoniae but does not significantly alter the natural oral or nasopharyngeal microbiota of mice.

    PMID: 16861686 [PubMed - indexed for MEDLINE]

    PMCID: PMC1539618

    Supplemental Content

    Click here to read Click here to read

    Patient drug information

    • Pneumococcal Polysaccharide Vaccine (Pneumovax® 23)

      Pneumococcal disease is caused byStreptococcus pneumoniae bacteria. It is a leading cause of vaccine-preventable illness and death in the United States. Anyone can get pneumococcal disease, but some people are at greater...